Clessbio’s first core technology platform centers on the development of long-acting fusion proteins. The company has filed a patent application for its self-developed "Long-Acting Fusion Protein Technology Platform". This platform employs molecular engineering strategies to systematically optimize pharmacokinetic and safety properties, with core innovations including:

Target protein-Fc fusion architecture: Therapeutic proteins (e.g., hormones, cytokines) are fused to an antibody Fc fragment via rationally designed linkers.

Engineered FcRn binding domain: Drawing on antibody half-life extension technologies, point mutations such as YTE (M252Y/S254T/T256E) are introduced into the Fc region of the fusion protein. This significantly enhances its binding affinity for FcRn at acidic pH, thereby markedly extending its in vivo half-life through an enhanced FcRn-mediated recycling pathway.

Silenced effector function design: Key point mutations eliminate binding to FcγR and C1q, effectively abolishing antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) effects. This reduces potential immunogenicity risks and improves therapeutic safety.

This platform technology is designed to achieve long-acting properties and a high safety profile for fusion proteins, thereby providing an optimized therapeutic solution for the treatment of chronic diseases.